Treatment
7Achondroplasia therapy reference (2026)
Reference snapshot of achondroplasia care across supportive, surgical, and disease-modifying tiers.
Phenylketonuria therapy reference (2026)
Reference snapshot of PKU therapy across newborn-screened, paediatric, and adult populations.
Spinal muscular atrophy therapy reference (2026)
Reference snapshot of SMA therapy options across newborn-screened, symptomatic infant, child, and adult populations.
Hereditary angioedema therapy reference (2026)
Reference snapshot of HAE prophylaxis and on-demand therapy options.
Antisense oligonucleotide platform landscape (2026 reference)
Reference snapshot of approved ASO therapies, late-stage programs, and the delivery and chemistry platforms behind them.
Rare disease enzyme replacement therapy landscape, 2026 mid-year reference
Reference layout of the enzyme replacement therapy class in rare disease as of mid-2026: approved assets across lysosomal storage disease, the next-generation engineered-enzyme programs, the gene therapy alternatives, and the live commercial questions including chronic-infusion burden and CNS access.
Approved gene therapies by indication, 2026 mid-year reference
Reference layout of approved in vivo and ex vivo gene therapies as of mid-2026: indications, mechanism, delivery vector or platform, regulatory pathway, and the live commercial questions for each.